STAT+: Under a new leader, the FDA’s biologics center moves to steady itself after stormy chapter
After his predecessor's turbulent tenure, Karim Mikhail is working to restore staff morale and revisit controversial rejections.
Read the full articleYou might also wanna read
AstraZeneca CEO: ‘Biology will catch up with me at some point’
Long-serving pharma chief Pascal Soriot hopes research and risk-taking will secure growth in China and US
ft.com·4d ago
Pharma CEOs' silence enables Trump administration's assault on U.S. biomedical research, argues Washington editor
Office of Management and Budget Director Russell Vought has poured gas on the foundations of science. Pharma CEOs should demand that Preside
biocentury.com·1mo ago
Post-BIO ins and outs: Rentschler and Syngene CEO appointments among big moves
Symeres and Axxam also join the fray, choosing a new CSO to lead their scientific strategy.
bioprocessintl.com·14d ago
HHS and FDA announce reforms to accelerate clinical trials and restore US research leadership
A welcome move from the FDA and HHS
writingruxandrabio.com·24d ago
How AI Will Transform Biopharma: The Sequence of Change Matters
How AI will transform biopharma—and why the sequence of change matters
a16z.news·25d ago
Replimune to resubmit melanoma drug for FDA approval after agency leadership changes
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
cnbc.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.